Jiangsu Alphamab Biopharmaceuticals Partners with Shanghai Jinmant Biotech for JSKN003 ADC

Alphamab Oncology (HKG: 9966), a biopharmaceutical company based in China, has announced that its wholly-owned subsidiary, Jiangsu Alphamab Biopharmaceuticals Co. Ltd, has entered into a licensing agreement with Shanghai Jinmant Biotech Co., Ltd, a subsidiary of CSPC Pharmaceutical Group Co., Ltd (HKG: 1093), for the development and commercialization of its HER2 bispecific antibody-drug conjugate (ADC) JSKN003. Under the agreement, Jinmant Biotech will receive exclusive rights to develop, sell, and commercialize JSKN003 for oncology indications in Mainland China (excluding Hong Kong, Macau, and Taiwan), and will become the Marketing Authorization Holder (MAH) for JSKN003 in Mainland China. The clinical development costs for JSKN003 will be borne by Jinmant Biotech. Alphamab Oncology retains the exclusive manufacturing rights for JSKN003 and is entitled to receive up to RMB 3.08 billion in upfront and milestone payments, including an initial payment of RMB 400 million and development milestone payments of RMB 300 million, as well as regulatory and sales milestone payments. Additionally, Alphamab Oncology is eligible to receive double-digit percentage royalties on the net sales of JSKN003 .-Fineline Info & Tech